THERAPYX, INC.

Basic Information

138 FARBER HALL
3435 MAIN STREET
BUFFALO, NY, 14214-8001

Company Profile

n/a

Additional Details

Field Value
DUNS: 145056607
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 6


  1. Therapy and Prophylaxis for Genital Tract Infection

    Amount: $1,498,000.00

    DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite publ ...

    SBIR Phase II 2014 Department of Health and Human Services
  2. A novel, multiparametric cardiac safety assay using human myocytes

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite publ ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

    Amount: $2,999,994.00

    DESCRIPTION (provided by applicant): Phase I studies established proof-of-principle for the efficacy of oral sustained-release TGF?1 (TPX-6001) and ATRA (TPX-7001) nanoparticles in the treatment of IB ...

    SBIR Phase II 2011 Department of Health and Human Services
  4. Co-encapsulation of IroN and IL-12 as an Extra-intestinal E. coli Vaccine.

    Amount: $292,501.00

    DESCRIPTION (provided by applicant): Despite recent advances in the treatment and prevention of infectious disease, the threat to world health continues to grow. The spread of new zoonotic viral stra ...

    SBIR Phase I 2008 Department of Health and Human Services
  5. Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

    Amount: $172,500.00

    DESCRIPTION (provided by applicant): The disorders collectively known as inflammatory bowel disease (IBD) include Crohn's disease (CD) and ulcerative colitis (UC) and affect up to one million people i ...

    SBIR Phase I 2008 Department of Health and Human Services
  6. Treatment of Type 2 Diabetes with Oral Administration of Nanoencapsulated GLP-1

    Amount: $144,961.00

    DESCRIPTION (provided by applicant): Type 2 diabetes mellitus is one of the leading causes of death and disability in the world. While current treatments prevent some of diabetes' more damaging compli ...

    SBIR Phase I 2006 Department of Health and Human Services
  7. TUMOR IMMUNOTHERAPY WITH BIODEGRADABLE MICROSPHERES

    Amount: $0.00

    DESCRIPTION (provided by applicant): Proof of principle for the feasibility of our proprietary tumor vaccination strategy involving the use of Interleukin-12-encapsulated microspheres has been demo ...

    SBIR Phase I 2003 Department of Health and Human Services
  8. TUMOR IMMUNOTHERAPY WITH BIODEGRADABLE MICROSPHERES

    Amount: $2,555,134.00

    DESCRIPTION (provided by applicant): Proof of principle for the feasibility of our proprietary tumor vaccination strategy involving the use of Interleukin-12-encapsulated microspheres has been demo ...

    SBIR Phase II 2003 Department of Health and Human Services
  9. TUMOR VACCINE:COVALENT LINK OF ANTIGEN TO DENDRITIC CELL

    Amount: $158,517.00

    DESCRIPTION (provided by applicant): The ability of dendritic cells (DC) to activate naive T-cells has made them targets for the design of enhanced vaccination protocols. DC loaded with tumor antigen ...

    SBIR Phase I 2002 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government